Download fulltext
HTML
Minami, T., Yamana, H., Shigemi, D., Matsui, H., Fushimi, K., & Yasunaga, H. (2019). Artificial colloids versus human albumin for the treatment of ovarian hyperstimulation syndrome: A retrospective cohort study. International Journal of Reproductive BioMedicine (IJRM), 17(10). https://doi.org/10.18502/ijrm.v17i10.5287
https://doi.org/10.18502/ijrm.v17i10.5287
statistics
- 149 Abstract Views
- 97 PDF Views
- 0 HTML Views
- Cited by 3 articles
authors
-
Tetsuji Minami
Tetsuji Minami
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan; Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
-
Hayato Yamana
Hayato Yamana
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
-
Daisuke Shigemi
Daisuke Shigemi
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
-
Hiroki Matsui
Hiroki Matsui
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
-
Kiyohide Fushimi
Kiyohide Fushimi
Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
-
Hideo Yasunaga
Hideo Yasunaga
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Published Date
- Oct 1, 2019
Artificial colloids versus human albumin for the treatment of ovarian hyperstimulation syndrome: A retrospective cohort study
Abstract
Background: The optimal colloid solution for the treatment of ovarian hyperstimulation syndrome (OHSS) remains to be established.
Objective: We aimed to compare artificial colloids (AC) with human albumin (HA) for the treatment of OHSS. Materials and Methods: In this retrospective cohort study, data for OHSS participants were collected from a national inpatient database in Japan. The participants received intravenous fluid management with AC (n = 156) or HA (n = 127). We compared the two groups in terms of the length of stay, development of post-treatment complications, and termination surgery.
Results: In multivariable linear regression analyses for log-transformed length of stay with reference to the OHSS participants receiving AC, the regression coefficient (95% confidence interval) in participants receiving HA was 0.03 (-0.04-0.09, p = 0.42). Thromboembolism occurred in two participants in the HA group and three participants in the AC group. Two participants in the HA group suffered renal failure during hospitalization. No participants underwent termination surgery in the two groups.
Conclusions: The present results showed comparable efficacy between AC and HA for the treatment of OHSS. There were no significant differences in post-treatment complications between the two groups.
Key words: Ovarian hyperstimulation syndrome, Treatment, Colloid, Length of stay.
References
[1] Garcia-Velasco JA, Pellicer A. New concepts in the understanding of the ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 2003; 15: 251–256.
[2] Kwik M, Maxwell E. Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 2016; 28: 236–241.
[3] Borase H, Mathur R. Ovarian hyperstimulation syndrome: clinical features, prevention and management. Obstet Gynaecol Reprod Med 2012; 22: 186–190.
[4] Chen CD, Chen SU, Yang YS. Prevention and management of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynaecol 2012; 26: 817–827.
[5] Abramov Y, Fatum M, Abrahamov D, Schenker JG. Hydroxyethyl starch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 2001; 75: 1228–1230.
[6] Endo T, Kitajima Y, Hayashi T, Fujii M, Hata H, Azumaguchi A. Low-molecular-weight dextran infusion is more effective for the treatment of hemoconcentration due to severe ovarian hyperstimulation syndrome than human albumin infusion. Fertil Steril 2004; 82: 1449–1451.
[7] Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 44: 430–440.
[8] Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249–261.
[9] Crane J, Mundle W, Boucoiran I. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can 2014; 36: 1107–1116.
[10] Ministry of Health. [Labour and Welfare, List of drug price]. Available at: https://www.mhlw.go.jp/topics/2019/ 08/dl/tp20191001-01_02.pdf. Accessed September 16, 2019. (In Japanese)
[11] Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013; 310: 1809–1817.
[12] Kissler S, Neidhardt B, Siebzehnrubl E, Schmitt H, Tschaikowsky K, Wildt L. The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report. Eur J Obstet Gynecol Reprod Biol 2001; 99: 131–134.
[13] Jin S, Yu G, Hou R, Shen B, Jiang H. Effect of hemodilution in vitro with hydroxyethyl starch on hemostasis. Med Sci Monit 2017; 23: 2189–2197.
[14] Marcus MA, Vertommen JD, Van Aken H. Hydroxyethyl starch versus lactated Ringer’s solution in the chronic maternal-fetal sheep preparation: a pharmacodynamic and pharmacokinetic study. Anesth Analg 1995; 80: 949– 954.
[15] Stander S, Bone HG, Machens HG, Aberle T, Burchard W, Prien T, et al. Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 2002; 310: 279–287.
[16] Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901–907.
[17] Aramwit P, Pruksananonda K, Kasettratat N, Jammeechai K. Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization. Am J Health Syst Pharm 2008; 65: 1148–1153.
[18] Swanton A, Lighten A, Granne I, McVeigh E, Lavery S, Trew G, et al. Do women with ovaries of polycystic morphology without any other features of PCOS benefit from shortterm metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. Hum Reprod 2011; 26: 2178–2184.
[19] Lewis SR, Pritchard MW, Evans DJ, Butler AR, Alderson P, Smith AF, et al. Colloids versus crystalloids for fluid resuscitation in critically ill people. Cochrane Database Syst Rev 2018; 8: doi: 10.1002/14651858.CD000567.
[20] Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008; 23: 160–167.
[21] Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol 2017; 27: 476–482.
[2] Kwik M, Maxwell E. Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 2016; 28: 236–241.
[3] Borase H, Mathur R. Ovarian hyperstimulation syndrome: clinical features, prevention and management. Obstet Gynaecol Reprod Med 2012; 22: 186–190.
[4] Chen CD, Chen SU, Yang YS. Prevention and management of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynaecol 2012; 26: 817–827.
[5] Abramov Y, Fatum M, Abrahamov D, Schenker JG. Hydroxyethyl starch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 2001; 75: 1228–1230.
[6] Endo T, Kitajima Y, Hayashi T, Fujii M, Hata H, Azumaguchi A. Low-molecular-weight dextran infusion is more effective for the treatment of hemoconcentration due to severe ovarian hyperstimulation syndrome than human albumin infusion. Fertil Steril 2004; 82: 1449–1451.
[7] Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 44: 430–440.
[8] Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249–261.
[9] Crane J, Mundle W, Boucoiran I. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can 2014; 36: 1107–1116.
[10] Ministry of Health. [Labour and Welfare, List of drug price]. Available at: https://www.mhlw.go.jp/topics/2019/ 08/dl/tp20191001-01_02.pdf. Accessed September 16, 2019. (In Japanese)
[11] Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013; 310: 1809–1817.
[12] Kissler S, Neidhardt B, Siebzehnrubl E, Schmitt H, Tschaikowsky K, Wildt L. The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report. Eur J Obstet Gynecol Reprod Biol 2001; 99: 131–134.
[13] Jin S, Yu G, Hou R, Shen B, Jiang H. Effect of hemodilution in vitro with hydroxyethyl starch on hemostasis. Med Sci Monit 2017; 23: 2189–2197.
[14] Marcus MA, Vertommen JD, Van Aken H. Hydroxyethyl starch versus lactated Ringer’s solution in the chronic maternal-fetal sheep preparation: a pharmacodynamic and pharmacokinetic study. Anesth Analg 1995; 80: 949– 954.
[15] Stander S, Bone HG, Machens HG, Aberle T, Burchard W, Prien T, et al. Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 2002; 310: 279–287.
[16] Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901–907.
[17] Aramwit P, Pruksananonda K, Kasettratat N, Jammeechai K. Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization. Am J Health Syst Pharm 2008; 65: 1148–1153.
[18] Swanton A, Lighten A, Granne I, McVeigh E, Lavery S, Trew G, et al. Do women with ovaries of polycystic morphology without any other features of PCOS benefit from shortterm metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. Hum Reprod 2011; 26: 2178–2184.
[19] Lewis SR, Pritchard MW, Evans DJ, Butler AR, Alderson P, Smith AF, et al. Colloids versus crystalloids for fluid resuscitation in critically ill people. Cochrane Database Syst Rev 2018; 8: doi: 10.1002/14651858.CD000567.
[20] Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008; 23: 160–167.
[21] Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol 2017; 27: 476–482.